Pembrolizumab plus chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.

Basit Öğe Kaydı
dc.authorid0000-0003-4389-8124
dc.contributor.authorTewari, Krishnansu Sujata
dc.contributor.authorColombo, Nicoletta
dc.contributor.authorMonk, Bradley J.
dc.contributor.authorDubot, Coraline
dc.contributor.authorCaceres, M. Valeria
dc.contributor.authorHasegawa, Kosei
dc.contributor.authorShapira-Frommer, Ronnie
dc.date.accessioned2025-05-10T19:27:40Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Clin Oncol
dc.description.sponsorshipMerck Sharp Dohme Corp.
dc.description.sponsorshipMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7027
dc.identifier.volume40
dc.identifier.wosWOS:000863680301558
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titlePembrolizumab plus chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu